Ginkgo Bioworks Holdings Inc. Class A

The Ark Invest CEO also sold off millions of her favorite stock to invest in this one.

Ark Invest really likes this technology stock.

Ark Invest loves its tech stocks.

Ark Invest is embracing biotechnology.

Some aren't sure about this stock, but Wood remains steadfast.

The synthetic biology pioneer and the Kingdom of Saudi Arabia are exploring a technology partnership.

Ginkgo's recent focus on drug development programs will avoid certain manufacturing risks. It also may hurt the stock's valuation.

The new CEO is a perfect fit for the company's growth plans. Sales will decline sharply anyway.

The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.

The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.

Cathie Wood, CEO of Ark Investment Management, reversed her stance on two major technology companies.

How many years of future revenue and earnings were investors paying for in 2021? In some cases, quite a few.

Wood's flagship Ark Innovation ETF has fallen 54% this year, as her technology companies have stumbled.

The return of Wood's flagship Ark Innovation ETF lagged behind the S&P 500 for the five years through July 5.

Worried about a recession? These cashed-up biotech stocks aren't sweating it.

The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.

Ark also sold four stocks, including a defense contractor and a financial management software company.

Ark also purchased an e-commerce company and sold more of an EV maker.

Wood's flagship fund has seen an inflow of investment dollars this year, despite falling in value.

It is refreshing to see more aggressive trading action in higher volatility stocks.

Money-losing companies aren't the place to hide out during a bear market with rising interest rates, so trade in them with your eyes wide open and be ready to act quickly.

The rotation was big, but the Volatility Index barely moved. Let's check that whirling noise under the hood.

Let's review areas that are hot, those that are not, and how to position though January.

There was a lot of reaction to the Ginkgo Bioworks Holdings short report on Twitter Wednesday not too long after it was published.

In two or three months, you won't hear a word on this again much like we've seen on so many other names.

Ginkgo Bioworks has great potential for science and investors.

The mixed action on Monday is not a negative -- and here's why SPACs are getting interesting again.

But aggressive action by retail traders is one reason that I'm not too worried about a substantial correction at this time.

We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.

After lowering interest rates to zero, the government is now printing money to revive the economy.

The health care industry has been ripe for M&A and this biotech company picked some juicy fruit.

The priorities remain housing and jobs, and until both have a resolution, the market will be range-bound.

I'm confident that my strategy of focusing on health care and consumer goods names will pay off.

Recent action in the industry is a sign of things to come.

Financial stocks took the brunt of this week's difficult market action, and we remain in wait-and-see mode.

Negative news regarding psoriasis drug Raptiva creates an opportunity to pick up shares of this name.

During a busy week for the model portfolio, we added a new holding and saw two names report strong earnings results.

We were able to use the market's volatility to make a few advantageous moves in the model portfolio this week.

The distressed retail chain files for Chapter 11 bankruptcy, facing macroeconomic headwinds.

Dr. Alan Baratz sits down with TheStreet to explain why Nvidia's CEO is "dead wrong" about quantum computing's future.

Here’s what could be next for AMD and its AI ambitions.